Pharmaceutical

TORL scores $158m in Series B2 to advance ADC cancer therapies

TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.

Apr 11, 2024 - 00:00
TORL scores $158m in Series B2 to advance ADC cancer therapies
TORL plans to use the funds to advance the clinical development of its antibody-drug conjugate (ADC) pipeline.
Read the original article

Tags:

Previous Article

Lisata wins FDA orphan drug status for bone cancer candidate

Next Article

Acceleron Pharma gets grant for treatment of spinal muscular atrophy using ALK4:...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Vivoryon issues updates on its Alzheimer’s therapy programme

Vivoryon issues updates on its Alzheimer’s therapy prog...

Jul 17, 2023

STAT+: Moonlake’s less-than-transparent data disclosures produced a cash windfall. Risks remain

STAT+: Moonlake’s less-than-transparent data disclosure...

Jun 28, 2023

STAT+: Damages from tornado at Pfizer plant could compound challenges of drug shortages

STAT+: Damages from tornado at Pfizer plant could compo...

Jul 20, 2023